Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1486 AL 1500

Environmental Toxins and Alzheimer's Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation

Dhapola R, Sharma P, Kumari S, Bhatti JS, HariKrishnaReddy D.

Mol Neurobiol. 2024 Jun;61(6):3657-3677. doi: 10.1007/s12035-023-03805-x. Epub 2023 Nov 25.

Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment

Chaves JCS, Dando SJ, White AR, Oikari LE.

Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166967. doi: 10.1016/j.bbadis.2023.166967. Epub 2023 Nov 24.

TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease

Shulman M, Kong J, O'Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB.

Nat Aging. 2023 Dec;3(12):1591-1601. doi: 10.1038/s43587-023-00523-w. Epub 2023 Nov 27.

Targeting synapse function and loss for treatment of neurodegenerative diseases

Dejanovic B, Sheng M, Hanson JE.

Nat Rev Drug Discov. 2024 Jan;23(1):23-42. doi: 10.1038/s41573-023-00823-1. Epub 2023 Nov 27.

Pathogenesis of Depression in Alzheimer's Disease

Zhan Q, Kong F, Shao S, Zhang B, Huang S.

Neurochem Res. 2024 Mar;49(3):548-556. doi: 10.1007/s11064-023-04061-0. Epub 2023 Nov 28.

Alzheimer Disease: A New Beginning in Therapeutics

Honig LS.

Alzheimer Dis Assoc Disord. 2023 Oct-Dec 01;37(4):267-269. doi: 10.1097/WAD.0000000000000592. Epub 2023 Nov 28.

Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer's Disease

Rajput S, Malviya R, Bahadur S, Puri D.

Curr Pharm Des. 2023;29(35):2802-2813. doi: 10.2174/0113816128274618231105173031.

The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer's Disease

Yan H, Feng L, Li M.

Drug Des Devel Ther. 2023 Nov 13;17:3295-3323. doi: 10.2147/DDDT.S380612. eCollection 2023.

Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease

Marei HE, Khan MUA, Hasan A.

Cell Mol Biol Lett. 2023 Nov 30;28(1):98. doi: 10.1186/s11658-023-00504-2.

A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease

Kashif M, Sivaprakasam P, Vijendra P, Waseem M, Pandurangan AK.

Curr Pharm Des. 2023;29(43):3428-3441. doi: 10.2174/0113816128264355231121064704.

Targets, trials and tribulations in Alzheimer therapeutics

Gharat R, Dixit G, Khambete M, Prabhu A.

Eur J Pharmacol. 2024 Jan 5;962:176230. doi: 10.1016/j.ejphar.2023.176230. Epub 2023 Dec 1.

Therapeutic potential of natural products against Alzheimer's disease via autophagic removal of Aβ

Hu M, Ying X, Zheng M, Wang C, Li Q, Gu L, Zhang X.

Brain Res Bull. 2024 Jan;206:110835. doi: 10.1016/j.brainresbull.2023.110835. Epub 2023 Dec 1.

Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer's Disease

Jin S, Guan X, Min D.

Curr Alzheimer Res. 2023;20(8):588-602. doi: 10.2174/0115672050272577231120060909.

Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease

Shukla AK, Misra S.

J Basic Clin Physiol Pharmacol. 2023 Dec 6;35(1-2):25-29. doi: 10.1515/jbcpp-2023-0176. eCollection 2024 Jan 1.

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer's disease: A meta-analysis

Zang L, Liu X, Li Y, Liu J, Lu Q, Zhang Y, Meng Q.

PLoS One. 2023 Dec 6;18(12):e0293977. doi: 10.1371/journal.pone.0293977. eCollection 2023.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias